SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo
Therefore, SEMA3B appears to be an interesting biomarker in the context of intestinal inflammation, which deserves further validation in larger cohorts. Nonetheless, based on our <i>in vivo</i> results, the implication of this factor in the development of colitis seems to be minimal.
Authors
- Laura Arosa (ORCID: https://orcid.org/0000-0001-9661-3191)
- Javier Conde-Aranda
- Beatriz Malvar-Fernández
- José Antúnez-López
- Samuel García
Institutions
- Universidade de Santiago de Compostela (ES)
- University Hospital Complex Of Vigo (ES)
- Galicia Sur Biomedical Foundation (ES)
- Complejo Hospitalario Universitario de Santiago (ES)
- Instituto de Investigación Sanitaria de Santiago (ES)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-04
- DOI
- https://doi.org/10.3389/fimmu.2026.1677130
- Primary Topic
- Axon Guidance and Neuronal Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission
- Instituto de Salud Carlos III